版本:
中国

BRIEF-Soligenix says findings expected to facilitate potential approval of Rivax product

April 19 Soligenix Inc:

* Soligenix Inc - results from its ricin toxin vaccine (rivax™) development program will be presented at 20(th) annual conference on vaccine research

* Soligenix Inc - findings are expected to facilitate potential approval of Rivax product under U.S. FDA "animal rule"

* Soligenix Inc - Rivax has demonstrated "significantly enhanced" thermostability and 100% protection in preclinical ricin aerosol challenge models Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐